43分
Revolutionizing Medicine: DoseMeRx's Journey to Smarter Dosing! Life Science Success
-
- 生命科学
Paul Edwards is the President and CEO of DoseMeRx. He has been a Senior Executive with Merck and GSK, and start-ups including ILUM Health Solutions, Infectious Disease Connect, and TrackMy Solutions. He has an extensive history in infectious disease, antimicrobial stewardship, and precision medicine.
Guest Introduction: Paul Edwards, the President and CEO of DoseMeRx, shares his extensive background in the pharmaceutical industry, including roles at Merck, GSK, and various startups, focusing on antibiotics and infectious diseases.
Pharmaceutical Journey: Paul discusses his career progression from selling macrolides to leading infectious disease units and moving to the U.S. to transform commercial models at Merck, emphasizing the importance of real-world data over clinical trial data.
DoseMeRx Focus: DoseMeRx specializes in precise dosing for critically ill patients using therapeutic drug monitoring, particularly for injectable antibiotics, aiming to provide accurate dosing information through web-based and integrated models within hospital systems.
Challenges and Future of Medicine: Paul highlights the importance of antimicrobial stewardship, pharmacogenomics, and personalized medicine in improving patient care and expresses concerns about the current insurance and payment systems based on actuarial science.
Paul Edwards is the President and CEO of DoseMeRx. He has been a Senior Executive with Merck and GSK, and start-ups including ILUM Health Solutions, Infectious Disease Connect, and TrackMy Solutions. He has an extensive history in infectious disease, antimicrobial stewardship, and precision medicine.
Guest Introduction: Paul Edwards, the President and CEO of DoseMeRx, shares his extensive background in the pharmaceutical industry, including roles at Merck, GSK, and various startups, focusing on antibiotics and infectious diseases.
Pharmaceutical Journey: Paul discusses his career progression from selling macrolides to leading infectious disease units and moving to the U.S. to transform commercial models at Merck, emphasizing the importance of real-world data over clinical trial data.
DoseMeRx Focus: DoseMeRx specializes in precise dosing for critically ill patients using therapeutic drug monitoring, particularly for injectable antibiotics, aiming to provide accurate dosing information through web-based and integrated models within hospital systems.
Challenges and Future of Medicine: Paul highlights the importance of antimicrobial stewardship, pharmacogenomics, and personalized medicine in improving patient care and expresses concerns about the current insurance and payment systems based on actuarial science.
43分